8.77
+0.31(+3.66%)
Currency In USD
Address
195 Church Street
New Haven, CT 06510
United States of America
Phone
203 304 2499
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
May 07, 2019
| Name | Title | Pay | Year Born |
| Ms. Jennifer L. Good | Co-Founder, Chief Executive Officer, President & Director | 987,254 | 1965 |
| Dr. Thomas R. Sciascia M.D. | Co-Founder & Chief Scientific Officer | 551,426 | 1953 |
| Ms. Lisa Delfini | Chief Financial Officer | 604,679 | 1971 |
| Dr. James V. Cassella Ph.D. | Chief Development Officer | 671,632 | 1955 |
| Mr. Farrell Simon Pharm.D. | Chief Commercial Officer | 0 | N/A |
| Katie McManus | Communications Manager | 0 | N/A |
| Mr. Christopher Galletta | Controller & Chief Accounting Officer | 0 | 1978 |
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.